Xience™ Stent: Protecting Patients with Short DAPT Needs
Dual antiplatelet therapy (DAPT) duration often depends on the patient—and it may depend on the stent as well.
XIENCE™ Stent Has the Largest Body of DAPT Patient Evidence3
XIENCE™ Stent is the only DES with results showing 1-month DAPT data and 3-month DAPT data for both aspirin and P2Y12 inhibitor monotherapy—including data on patients at high bleeding risk (HBR).4
Among all 3 categories outlined above—aspirin monotherapy, P2Y12 inhibitor monotherapy and HBR patients—XIENCE™ Stent data revealed very low rates of stent thrombosis (ST) at 12 months.5
≤ 0.3% Definite ST At 1 Year5
Comparison of Short DAPT Studies by Stent Type
XIENCE 28 and XIENCE 90 Study Results6
XIENCE™ Stent Short DAPT: Ischemic Events
Among HBR patients, XIENCE™ Stent with 1-month or 3-month DAPT reduced severe bleeding with no increase in ischemic events, including myocardial infarction (MI) and all death.6
XIENCE 28: 1-month DAPT in HBR Patients
XIENCE 28: All Death or MI
Between 1 and 6 months
XIENCE 90: 3-month DAPT in HBR Patients
XIENCE 90: All Death or MI
Between 3 and 12 months
XIENCE™ Stent Short DAPT: Reduced Severe Bleeding
In the same HBR population, XIENCE™ Stent with 1-month or 3-month DAPT reduced severe bleeding with no increase in ischemic events.6,*
XIENCE 28: BARC 3-5 Bleeding
Between 1 and 6 months
XIENCE 90: BARC 3-5 Bleeding
Between 3 and 12 months
*Propensity score stratified analysis for BARC 3-5 bleeding was not pre-specified. BARC 2-5 was a powered secondary endpoint. In both studies, for BARC 2-5, XIENCE™ Stent showed numerically lower bleeding rate for 1-month or 3-month DAPT versus 6-month DAPT or 12-month DAPT, respectively.
XIENCE™ Stent Short DAPT: Continued Low Stent Thrombosis
XIENCE™ Stent is recognized for its low ST rate, and it is significantly more anti-thrombotic than other DES.7 This is evident even with short DAPT data. XIENCE™ Stent with 1-month DAPT showed no increase in ST vs 6-month DAPT—with an ST rate of 0.3%. Similarly, the 3-month DAPT showed an ST rate of 0.2%.6
XIENCE 28: Stent Thrombosis
Between 1 and 6 months
ARC : Definite/Probable ST
XIENCE 90: Stent Thrombosis
Between 3 and 12 months
ARC : Definite/Probable ST
XIENCE™ Stent Is Anti-Thrombotic: Suited for Short DAPT
The XIENCE™ Stent is also recognized as being significantly more anti-thrombotic than other DES on the market. As shown in the study findings, XIENCE™ Stent reveals significantly less (p < 0.01) platelet adhesion—shown in red in the confocal microscopy images—than other DES, and platelet adhesion is an important factor in stent thrombosis.8 These findings suggest that this stent choice “may be ideally suited for very short-term DAPT.”8
STOPDAPT Studies: 1-Month DAPT and 3-Month DAPT in All-Comers Population9,10
STOPDAPT9 and STOPDAPT 210 were prospective trials of the XIENCE™ Stent that studied DAPT cessation at 3 months and 1 month, respectively
STOPDAPT 2 Trial: 1-Month DAPT Superior to 12-Month DAPT10
The STOPDAPT 2 trial revealed that 1-month DAPT demonstrated superior safety over 12-month DAPT for the primary endpoint of net adverse cardiovascular events (NACE). NACE included cardiovascular death, myocardial infarction (MI), definite ST, stroke, or thrombolysis in MI (TIMI) major/minor bleeding. All of the 3,009 patients in this randomized, controlled trial were treated with XIENCE™ Stent.10
Significantly Lower NACE* with 1-Month DAPT
Significantly Lower Bleeding Events* with 1‑Month DAPT
Comparable Ischemic Event Rates* with 1‑Month DAPT
Successful PCI using CoCr everolimus-eluting stent: XIENCE™
Eligible for DAPT (aspirin/P2Y12 receptor blocker) for 1 year
Patients who need oral anticoagulants
History of intracranial bleeding
Major in-hospital complications (MI/stroke/major bleeding)
STOPDAPT Study: XIENCE™ Stent with 3-Month DAPT Is Feasible9
STOPDAPT9 was the first prospective trial to study DAPT cessation at 3 months after implantation. Among other 1-year outcomes, the XIENCE™ Stent rate of stent thrombosis was 0.0%.
STOPDAPT Study Demonstrates Feasibility of XIENCE™ Stent with 3-Month DAPT9
“Stopping DAPT at 3 months in selected patients after [XIENCE™ Stent] implantation was at least as safe as the prolonged DAPT regimen adopted in the historical control group.”
— Masahiro Natsuaki, MD, STOPDAPT Trial9
Expert Panel Discussion on STOPDAPT 2 and Short DAPT Strategies for PCI Patients
Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.
Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.